Fig. 6: Inhibition/depletion of DYRK1A sensitizes cancer cells to G1/S phase-targeting chemotherapy drugs in vitro. | npj Precision Oncology

Fig. 6: Inhibition/depletion of DYRK1A sensitizes cancer cells to G1/S phase-targeting chemotherapy drugs in vitro.

From: Targeting the DYRK1A kinase prevents cancer progression and metastasis and promotes cancer cells response to G1/S targeting chemotherapy drugs

Fig. 6

Dose-response curves after various concentrations of chemotherapeutic drugs (topotecan, cisplatin and paclitaxel, 48 h treatments) in DYRK1A-KOs and NT-KOs for (a) HCT-116, (b) SUM-159 and (c) MDA-MB-231 cells or parental HCT-116 (d) and MDA-MB-231 (e) cells co-treated with harmine (IC25 and IC50). Error bars represent ±SEM of three independent experiments. * Represent the p-value (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001) generated using two-sided T-test.

Back to article page